Patents by Inventor Roger Sherwood

Roger Sherwood has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bacterial nitroreductase for the reduction of CB1954 and analogues thereof to a cytotoxic form
    Patent number: 5977065
    Abstract: A prodrug of the formula (I): ##STR1## where R.sup.1 is a group such that the compound R.sup.1 NH.sub.2 represents actinomycin D, doxorubicin, mitomycin C, or a nitrogen mustard of the formula (IV): ##STR2## a prodrug of the formula (II): ##STR3## where R.sup.2 is a group such that the compound R.sup.2 OH is a phenolic nitrogen mustard; and processes whereby the prodrugs shown above are made in which a prodrug precursor compound is reacted with 4-nitrobenzyl chloroformate under anhydrous conditions.
    Type: Grant
    Filed: June 1, 1998
    Date of Patent: November 2, 1999
    Assignee: Cancer Research Campaign Technology Limited
    Inventors: Gillian Anlezark, Roger Melton, Roger Sherwood, Thomas Connors, Frank Friedlos, Michael Jarman, Richard Knox, Anthony Mauger, Caroline Joy Springer
  • Bacterial nitroreductase gene-prodrug system
    Patent number: 5958682
    Abstract: A system is disclosed which comprises: (i) a viral vector comprising a nucleotide sequence encoding a nitroreductase, which nitroreductase is capable of converting a prodrug into a cytotoxic drug; and (ii) a prodrug capable of being converted into a cytotoxic drug by the nitroreductase encoded by the vector. The disclosed invention also includes methods for killing cancerous and/or non-cancerous cells using the system described above. Included in the invention are methods for killing cells in vitro by introducing a vector encoding a nitroreductase into the cells, and then by providing a prodrug to the cells growing in vitro. Also included are methods in which cancerous and/or non-cancerous cells are killed in vivo in an animal or human by administering the vector and prodrug directly to cells of the animal or human.
    Type: Grant
    Filed: July 1, 1996
    Date of Patent: September 28, 1999
    Assignee: Cancer Research Campaign Technology Limited
    Inventors: Thomas Connors, Richard Knox, Roger Sherwood
  • Bacterial nitroreductase for the reduction of CB 1954 and analogues thereof to a cytotoxic form
    Patent number: 5780585
    Abstract: A prodrug of the formula (I): ##STR1## where R.sup.1 is a group such that the compound R--NH.sub.2 represents actinomycin D, doxorubicin, mitomycin C, or a nitrogen mustard of the formula (IV): ##STR2## a prodrug of the formula (II): ##STR3## where R.sup.1 is a group such that the compound R.sup.2 OH is a phenolic nitrogen mustard; and processes whereby the prodrugs shown above are made in which a prodrug precursor compound is reacted with 4-nitrobenzyl chloroformate under anhydrous conditions.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 14, 1998
    Assignee: Cancer Research Campaign Technology Limited
    Inventors: Gillian Anlezark, Roger Melton, Roger Sherwood, Thomas Connors, Frank Friedlos, Michael Jarman, Richard Knox, Anthony Mauger, Caroline Joy Springer
  • Bacterial nitroreductase for the reduction of CB 1954 and analogues thereof to a cytotoxic form
    Patent number: 5633158
    Abstract: The invention provides a nitroreductase, obtainable from a bacterium having the following characteristics as exemplified by examples isolated from Escherichia coli B and Bacillus amyloliquifaciens: 1) it is flavoprotein having a molecular weight in the range of 20-60 Kilodaltons; 2) it requires either NADH or NAD(P)H or analogues thereof as a cofactor; 3) it has a Km for NADH or NAD(P)H in the range of 1-100 .mu.M; and 4) it is capable of reducing either or both nitro groups of CB1954 and analogues thereof to a cytotoxic form e.g. the hydroxylamine. The sequence of one such nitroreductase is shown in Seq. ID No. 1. The nitroreductase may be conjugated to a tumor targeting agent such as a monoclonal antibody and used to convert prodrugs into active antitumor agents. Such prodrugs and drugs are also provided.
    Type: Grant
    Filed: July 27, 1994
    Date of Patent: May 27, 1997
    Assignee: Cancer Research Campaign Technology Limited
    Inventors: Gillian Anlezark, Roger Melton, Roger Sherwood, Thomas Connors, Frank Friedlos, Michael Jarman, Richard Knox, Anthony Mauger